Viatris (VTRS) Stock
Key stats
- Market cap
- $24.14B
- Price / Earnings ratio
- -39.3x
- EPS (TTM)
- -$0.53
- Volume
- Loading
- 52-week high
- $20.86
- 52-week low
- $10.15
- Dividend yield
- 2.28%
- Dividend amount (latest)
- $0.12
- EPS vs analyst estimate
- +8.1%Q3 FY25 · $0.67 vs $0.62
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with VTRS
Recent news

Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
VTRS

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
VTRS

Why Did MA, LNG, VTRS Stocks Surge To 52-Week Highs?
Why Did MA, LNG, VTRS Stocks Surge To 52-Week Highs?
VTRS

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
VTRS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 75.42
- MACD 12/26/9
- 0.74
- EMA 9 of MACD
- 0.53
- MACD histogram
- 0.21
- SMA 50
- $17.96
- Price above SMA 50
- EMA 50
- $18.26
- Price above EMA 50
- SMA 200
- $16.16
- Price above SMA 200
- EMA 200
- $15.99
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.62 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
VTRS

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
VTRS

Why Did MA, LNG, VTRS Stocks Surge To 52-Week Highs?
Why Did MA, LNG, VTRS Stocks Surge To 52-Week Highs?
VTRS

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
VTRS

Why Did XOM, BTE, VTRS Jump To 52-Week Highs Today?
Why Did XOM, BTE, VTRS Jump To 52-Week Highs Today?
VTRS

Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
VTRS

IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
VTRS

Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term
Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term
VTRS

Here's Why Viatris (VTRS) is a Strong Value Stock
Here's Why Viatris (VTRS) is a Strong Value Stock
VTRS

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
VTRS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Viatris
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott Andrew Smith Ph.D. | CEO & Director | 1962 |
| Mr. Paul B. Campbell | Interim CFO, Chief Accounting Officer & Corporate Controller | 1967 |
| Mr. Andrew Enrietti | Chief Administrative & Transformation Officer | 1985 |
| Dr. Corinne M. Le Goff M.B.A., Pharm.D. | Chief Commercial Officer | 1965 |
| Mr. Ramkumar V. Rayapureddy | Chief Information Officer | — |
| Mr. William Szablewski C.F.A. | Head of Investor Relations & Capital Markets | — |
| Mr. Matthew Joseph Maletta | Chief Legal Officer | 1972 |
| Ms. Lara Ramsburg | Chief People & Corporate Affairs Officer | — |
| Mr. Philippe Martin | Chief R&D Officer | 1976 |
| Mr. Peter McCormick | Chief Supply Officer | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 75.42
- MACD 12/26/9
- 0.74
- EMA 9 of MACD
- 0.53
- MACD histogram
- 0.21
- SMA 50
- $17.96
- Price above SMA 50
- EMA 50
- $18.26
- Price above EMA 50
- SMA 200
- $16.16
- Price above SMA 200
- EMA 200
- $15.99
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $21.00
- High
- $26.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.4 | +11.9 | ||||||||||
| 2022 | +5.3 | -26.9 | +7.2 | -4.5 | +20.2 | -13.3 | -9.5 | -1.1 | -11.0 | +16.2 | +7.6 | -1.0 |
| 2023 | +6.9 | -7.0 | -14.9 | -2.9 | -2.2 | +8.7 | +6.5 | +5.2 | -8.6 | -11.4 | +2.9 | +15.6 |
| 2024 | +3.3 | +4.2 | -5.2 | -3.1 | -8.9 | +0.5 | +13.9 | +1.0 | -2.4 | +1.0 | +12.7 | -5.7 |
| 2025 | -9.2 | -16.4 | -6.6 | -2.1 | +3.8 | +2.8 | -4.8 | +19.8 | -6.3 | +2.7 | +1.5 | +16.4 |
| 2026 | +5.1 | +9.1 | -13.9 | +9.6 | +8.1 | +0.4 | +8.5 | -6.4 | +6.6 | +9.0 | +11.7 |



